Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Completed 115Recruiting 107Unknown 75Active not recruiting 52Not yet recruiting 41Withdrawn 18Terminated 16Suspended 3Enrolling by invitation 3Approved for marketing 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1

Conditions

Thyroid Neoplasms 1Liver Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 16Nivolumab 10Paclitaxel 9Cisplatin 9Gemcitabine 8Bevacizumab 8venetoclax 7Vincristine 7Prednisone 7Doxorubicin 7Azacitidine 7pembrolizumab 6Radiotherapy 6Radiosurgery 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Taxes 5Surgical Procedures, Operative 5Rituximab 5Oxaliplatin 5Irinotecan 5Everolimus 5Capecitabine 5fludarabine phosphate 4fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × lenvatinib × Clear all
NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03139747 2021-10-15

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Thomas Jefferson University

Phase 2 Suspended
5 enrolled
Head & Neck

Thyroid Neoplasms

NCT03779100 2019-01-28

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Sun Yat-sen University

Phase 2 Suspended
25 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡